JUL 29, 2020 10:30 AM PDT

Will We Have a COVID-19 Vaccine by Year-End?

WRITTEN BY: Annie Lennon

This week, pharmaceutical companies Moderna and Pfizer launched giant Phase III 30,000-subject trials for their COVID-19 vaccines. Both say that their vaccines may be available for general use by the end of the year. 

The vaccines are based upon a relatively new practice in which synthetic molecules that mimic the coronavirus are injected into patients instead of the virus itself. In doing so, they teach the immune system to fend off the real thing, while being safe from potential side effects of having it introduced to the body. 

Although faster than traditional production methods and thus easily scalable, as the practice is relatively new, it does not have an extensive track record for efficacy. 

Nevertheless, announcements for the trials come as a part of the US government-funded COVID-19 Prevention Network that plans to roll out studies of leading vaccine candidates every month- each with 30,000 newly recruited volunteers. Aside from seeing if the vaccines work, researchers hope to verify each vaccine's safety profile and then compare results. 

All of this means that large numbers of people will be required to partake in trials, which can often be problematic. Dr. Larry Corey, a virologist who helps oversee the study sites, has said, however, that over 150,000 Americans have already signaled interest in the treatment in online registries. 

While Moderna has received almost $1 billion from the US government to help roll out its vaccine, Pfizer has agreed to sell enough vaccines for 50 million people in the US for around $2 billion should their vaccine work. 

Pfizer has also said that it aims to have around 1.3 billion doses available by the end of 2021- enough to treat 650 million people at two doses each. Meanwhile, Moderna aims to manufacture between 500 million and 1 billion doses per year.

 

Sources: CNBCWashington PostReuters

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUL 17, 2020
Immunology
More Potential Antibody Therapies for COVID Emerge
JUL 17, 2020
More Potential Antibody Therapies for COVID Emerge
When it comes to clinical countermeasures against COVID-19, one class of molecules stands out among the others: antibodi ...
JUL 28, 2020
Cardiology
Looking to Newborns for Help Healing Scars on the Heart
JUL 28, 2020
Looking to Newborns for Help Healing Scars on the Heart
Scars are a badge of honor to many, but they are really just a consequence of the body’s repair response. The body ...
JUL 14, 2020
Drug Discovery & Development
How Cancer Cells Influence Drug Responses
JUL 14, 2020
How Cancer Cells Influence Drug Responses
When studying a large number of brain samples, researchers were able to characterize how changes in cells influence drug ...
JUL 25, 2020
Drug Discovery & Development
New Method for Targeting The Herpes Virus
JUL 25, 2020
New Method for Targeting The Herpes Virus
A new way for treating the human herpes viruses was recently discovered by researchers at Lund University in Sweden. The ...
AUG 17, 2020
Drug Discovery & Development
How Do Drugs Treat Parasitic Infections?
AUG 17, 2020
How Do Drugs Treat Parasitic Infections?
How Do Medications Deal With Parasitic Infections? Researchers have been curious to know how a common medication battles ...
SEP 15, 2020
Drug Discovery & Development
Turmeric Better than Placebo for Osteoarthritis Pain
SEP 15, 2020
Turmeric Better than Placebo for Osteoarthritis Pain
Researchers from the University of Tasmania in Australia have found that an extract from turmeric is more effective than ...
Loading Comments...